GH Stock Analysis: Guardant Health | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 22.218m USD | 12M Return: 156.6% | US40131M1099 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 322M
Qual. Beats: -1
Rev. Trend: 99.6%
Qual. Beats: 9
Warnings
Tailwinds
Seasonality 8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Guardant Health, Inc. is a precision oncology company headquartered in Palo Alto, California, founded in 2011 and listed on NASDAQ since October 2018. The company sells blood and tissue-based genomic tests and related data products, primarily serving oncologists, biopharmaceutical drug developers, and health systems in the liquid biopsy segment of the cancer diagnostics market.
Its commercial test portfolio includes the Guardant360 CDx and Guardant360 Liquid assays for tumor mutation profiling, the Guardant Reveal test for molecular residual disease and recurrence monitoring, the Guardant360 Tissue test for solid tumor profiling, and the Shield blood test for colorectal cancer screening in adults.
Beyond diagnostic tests, Guardant offers research-use assays (GuardantINFINITY, GuardantOMNI), clinical-genomics data products (GuardantINFORM), and GuardantConnect, a software platform that links tested patients with relevant clinical trials. The company also provides companion diagnostic development, regulatory, and testing services, and maintains a strategic oncology drug development collaboration with Nuvalent, Inc.
- Shield CRC screening volume accelerates following Medicare reimbursement coverage
- Guardant360 liquid biopsy revenue faces competition from Natera and Caris
- Path to profitability hinges on Shield test gross margin expansion
| Net Income: -453.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 3.37 > 1.0 |
| NWC/Revenue: 86.69% < 20% (prev 77.82%; Δ 8.87% < -1%) |
| CFO/TA -0.10 > 3% & CFO -185.2m > Net Income -453.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (132.1m) vs 12m ago 6.41% < -2% |
| Gross Margin: 65.01% > 18% (prev 62.84%; Δ 2.17% > 0.5%) |
| Asset Turnover: 72.93% > 50% (prev 62.23%; Δ 10.71% > 0%) |
| Interest Coverage Ratio: -93.37 > 6 (EBIT TTM -449.7m / Interest Expense TTM 4.82m) |
| A: 0.54 (Total Current Assets 1.36b - Total Current Liabilities 339.0m) / Total Assets 1.91b |
| B: -1.69 (Retained Earnings -3.23b / Total Assets 1.91b) |
| C: -0.28 (EBIT TTM -449.7m / Avg Total Assets 1.62b) |
| D: -0.10 (Book Value of Equity -222.9m / Total Liabilities 2.14b) |
| Altman-Z'' = -3.95 = D |
| DSRI: 0.78 (Receivables 144.2m/130.3m, Revenue 1.18b/828.8m) |
| GMI: 0.97 (GM 62.84% / 65.01%) |
| AQI: 1.12 (AQ_t 0.13 / AQ_t-1 0.11) |
| SGI: 1.43 (Revenue 1.18b / 828.8m) |
| TATA: -0.14 (NI -453.4m - CFO -185.2m) / TA 1.91b) |
| Beneish M = -2.88 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at USD 167.47 with a total of 1,519,912 shares traded. Over the past week, the price has changed by -5.81%, over one month by +2.88%, over three months by +2.07% and over the past year by +156.62%.
Current recommended Stop Loss: 149.80 (which is 10.6% or 2.1 ATR below the current price).
Guardant Health has no consensus analysts rating.
| Analysts Target Price | 200.2 | 19.6% |
P/S = 18.779
P/B = 55.6696
Revenue TTM = 1.18b USD
EBIT TTM = -449.7m USD
EBITDA TTM = -411.2m USD
Long Term Debt = 1.50b USD (from longTermDebt, last quarter)
Short Term Debt = 27.8m USD (from shortTermDebt, last quarter)
Debt = 1.89b USD (from shortLongTermDebtTotal, last quarter) + Leases 194.1m
Net Debt = 837.6m USD (calculated: Debt 1.89b - CCE 1.05b)
Enterprise Value = 23.1b USD (22.2b + Debt 1.89b - CCE 1.05b)
Interest Coverage Ratio = -93.37 (Ebit TTM -449.7m / Interest Expense TTM 4.82m)
EV/FCF = -82.58x (Enterprise Value 23.1b / FCF TTM -279.2m)
FCF Yield = -1.21% (FCF TTM -279.2m / Enterprise Value 23.1b)
FCF Margin = -23.60% (FCF TTM -279.2m / Revenue TTM 1.18b)
Net Margin = -38.33% (Net Income TTM -453.4m / Revenue TTM 1.18b)
Gross Margin = 65.01% ((Revenue TTM 1.18b - Cost of Revenue TTM 413.9m) / Revenue TTM)
Gross Margin QoQ = 65.39% (prev 65.22%)
Tobins Q-Ratio = 12.06 (Enterprise Value 23.1b / Total Assets 1.91b)
Interest Expense / Debt = 0.25% (Interest Expense 4.82m / Debt 1.89b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -355.2m (EBIT -449.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.16 (Total Current Assets 1.36b / Total Current Liabilities 432.5m)
Debt / Equity = -8.49 (negative equity) (Debt 1.89b / totalStockholderEquity, last quarter -222.9m)
Debt / EBITDA = -2.04 (negative EBITDA) (Net Debt 837.6m / EBITDA -411.2m)
Debt / FCF = -3.00 (negative FCF - burning cash) (Net Debt 837.6m / FCF TTM -279.2m)
Total Stockholder Equity = -214.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.95% (Net Income -453.4m / Total Assets 1.91b)
RoE = 211.5% (negative equity) (Net Income TTM -453.4m / Total Stockholder Equity -214.4m)
RoCE = -34.90% (EBIT -449.7m / Capital Employed (Equity -214.4m + L.T.Debt 1.50b))
RoIC = -23.04% (negative operating profit) (NOPAT -355.2m / Invested Capital 1.54b)
WACC = 9.74% (E(22.2b)/V(24.1b) * Re(10.55%) + D(1.89b)/V(24.1b) * Rd(0.25%) * (1-Tc(0.21)))
Discount Rate = 10.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.04 | Cagr: 3.70%
[DCF] Fair Price = unknown (Cash Flow -279.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.46 | # QB: -1
Revenue Correlation: 99.64 | Revenue CAGR: 32.73% | SUE: 3.10 | # QB: 9
EPS current Quarter (2026-09-30): EPS=-0.31 | Chg30d=-2.83% | Revisions=+0% | Analysts=17
EPS current Year (2026-12-31): EPS=-1.47 | Chg30d=-0.78% | Revisions=-40% | GrowthEPS=+19.4% | GrowthRev=+38.2%
EPS next Year (2027-12-31): EPS=-0.41 | Chg30d=+6.71% | Revisions=+25% | GrowthEPS=+71.9% | GrowthRev=+35.1%
[Analyst] Revisions Ratio: -5% (up=9, down=10)